Amicus Therapeutics
Princeton, New Jersey, United States · Biotechnology, Health Care, Therapeutics
We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations.
Key facts
- Headquarters
- Princeton, New Jersey, United States
- Employees
- 500
- Industries
- Biotechnology, Health Care, Therapeutics
- Website
- amicusrx.com
- Company page
Recent activity at Amicus Therapeutics
- : SEC 8-K (5.02): On April 27, 2026, the Company notified the Nasdaq Global Select Market of the completion of a Merger, resulting in a change in control as the Company became a wholly owned subsidiary of its Parent. In connection with this change, all outstanding shares of Company Common Stock were converted into the right to receive the Merger Consideration, effectively terminating the stockholders' rights. The trading of Company Common Stock will be suspended on Nasdaq on April 28, 2026, and the Company plans to file for deregistration. Key parties included the Company and its Parent, highlighting significant strategic implications following this transaction.
- : SEC 8-K (8.01): On April 23, 2026, Amicus Therapeutics, Inc. announced that the Ministry of Economics and Finance in France granted clearance for its merger with BioMarin Pharmaceutical Inc. This French foreign direct investment clearance satisfies the final condition to the merger, allowing it to proceed as planned. The merger, first announced on December 19, 2025, is expected to close on April 27, 2026, making Amicus a wholly owned subsidiary of BioMarin. This clearance is crucial for the successful culmination of the merger and supports the strategic positioning of both companies in the biotech industry.
- : SEC 8-K (7.01): Amicus Therapeutics, Inc. reported that as of December 31, 2025, it had approximately $294 million in cash and marketable securities and estimated total net product revenues of approximately $634 million for the year 2025. This information was provided to BioMarin Pharmaceutical Inc. in connection with the proposed acquisition of Amicus by BioMarin, with the aim to fund the acquisition via a private placement of senior notes. The preliminary unaudited financial data was included in a memorandum dated January 26, 2026, aligning with the acquisition process timeline and significant strategic implications for both companies involved.
- : SEC 8-K (7.01):
- : SEC 8-K (1.01): On December 19, 2025, Amicus Therapeutics, Inc. entered into a Material Definitive Agreement in the form of an Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. and its wholly owned subsidiary Lynx Merger Sub 1, Inc. This agreement provides for the merger of Lynx Merger Sub 1, Inc. with and into Amicus Therapeutics, with Amicus surviving as a wholly owned subsidiary of BioMarin. The transaction is significant as it indicates a strategic consolidation in the biotechnology sector, enhancing BioMarin's portfolio. Key terms include that all shares of Amicus common stock will be converted at the effective time of the merger, although further financial details are pending.
- : SEC 8-K (1.01): On December 19, 2025, Amicus Therapeutics, Inc. entered into a significant merger agreement with BioMarin Pharmaceutical Inc. and its wholly owned subsidiary, Lynx Merger Sub 1, Inc. The Agreement and Plan of Merger stipulates that Lynx Merger Sub will merge with Amicus, with Amicus becoming a wholly owned subsidiary of BioMarin. Shareholders of Amicus will receive $14.50 in cash per share, with various considerations for unexercised options and restricted stock units. The completion of the merger is contingent on customary closing conditions, including avoiding any legal impediments or material adverse effects.
- : Amicus Therapeutics And Blackstone Enter Into $430 Million Strategic Financing Collaboration
- : Amicus Therapeutics Appoints Simon Harford as Chief
- : AMICUS THERAPEUTICS, INC.
- : AMICUS THERAPEUTICS INC
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Amicus Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Funding Round | Undisclosed |
| Oct 2021 | Venture | $199.9M |
| Jul 2016 | Seed | $4.7M |
Leadership
- Sébastien MARTEL, Executive Officer, Director
- Bradley Campbell, Director
- Simon Harford
Verified email and direct lines for Amicus Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Amicus Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Amicus Therapeutics in the news
- BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer - Fierce Pharma (May 12, 2026)
- Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - Yahoo Finance (Feb 20, 2026)
- BioMarin Completes Acquisition of Amicus Therapeutics - PR Newswire (Apr 27, 2026)
- FDA Defers Action on AT-GAA Treatment for Pompe Disease - NeurologyLive (Oct 28, 2022)
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewswire (Apr 30, 2025)
- Amicus Therapeutics (FOLD) Stock Price, News & Analysis $FOLD - MarketBeat (Jun 05, 2015)
Companies similar to Amicus Therapeutics
- Veristat · Biotechnology, Health Care, Therapeutics
- Acadia Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Debiopharm · Biotechnology, Health Care, Therapeutics
- Travere Therapeutics · Biotechnology, Health Care, Therapeutics
- bluebird bio · Biotechnology, Health Care, Therapeutics
About Amicus Therapeutics: questions and answers
What does Amicus Therapeutics do?
We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations.
Where is Amicus Therapeutics headquartered?
Amicus Therapeutics is headquartered in Princeton, New Jersey, United States.
How many employees does Amicus Therapeutics have?
Amicus Therapeutics has about 500 employees.
Has Amicus Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Amicus Therapeutics. The most recent, Funding Round of Undisclosed, was in Oct 2023.
What is the latest news on Amicus Therapeutics?
On Dec 19, 2025, SEC 8-K (5.02): On April 27, 2026, the Company notified the Nasdaq Global Select Market of the completion of a Merger, resulting in a change in control as the Company became a wholly owned subsidiary of its Parent. In connection with this change, all outstanding shares of Company Common Stock were c
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy